Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus
NCT02428192Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2015
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in Uterine leiomyosarcoma (ULMS), sponsored by National Cancer Institute. Started May 2015; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
Uterine leiomyosarcoma (ULMS)
Beyond the preview
Go deeper on NCT02428192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02428192.